295 related articles for article (PubMed ID: 23598981)
1. Targeting bone physiology for the treatment of metastatic prostate cancer.
Autio KA; Morris MJ
Clin Adv Hematol Oncol; 2013 Mar; 11(3):134-43. PubMed ID: 23598981
[TBL] [Abstract][Full Text] [Related]
2. Bone-targeting agents in prostate cancer.
Suzman DL; Boikos SA; Carducci MA
Cancer Metastasis Rev; 2014 Sep; 33(2-3):619-28. PubMed ID: 24398856
[TBL] [Abstract][Full Text] [Related]
3. Bone targeted therapies in metastatic castration-resistant prostate cancer.
Rajpar S; Fizazi K
Cancer J; 2013; 19(1):66-70. PubMed ID: 23337759
[TBL] [Abstract][Full Text] [Related]
4. Bone metastases in prostate cancer: a targeted approach.
Storey JA; Torti FM
Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.
Loberg RD; Logothetis CJ; Keller ET; Pienta KJ
J Clin Oncol; 2005 Nov; 23(32):8232-41. PubMed ID: 16278478
[TBL] [Abstract][Full Text] [Related]
6. Current trials using bone-targeting agents in prostate cancer.
Tu SM; Lin SH
Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
[TBL] [Abstract][Full Text] [Related]
7. Clinical approaches to osseous metastases in prostate cancer.
Morris MJ; Scher HI
Oncologist; 2003; 8(2):161-73. PubMed ID: 12697941
[TBL] [Abstract][Full Text] [Related]
8. Stromal targeted therapy in bone metastatic prostate cancer: promise delivered.
Sartor O; Goeckeler W; Bruland O
Asian J Androl; 2011 Nov; 13(6):783-4. PubMed ID: 21857688
[No Abstract] [Full Text] [Related]
9. Recent developments in treatments targeting castration-resistant prostate cancer bone metastases.
Loriot Y; Massard C; Fizazi K
Ann Oncol; 2012 May; 23(5):1085-1094. PubMed ID: 22267211
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in bone-targeted therapies of metastatic prostate cancer.
Deng X; He G; Liu J; Luo F; Peng X; Tang S; Gao Z; Lin Q; Keller JM; Yang T; Keller ET
Cancer Treat Rev; 2014 Jul; 40(6):730-8. PubMed ID: 24767837
[TBL] [Abstract][Full Text] [Related]
11. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
[TBL] [Abstract][Full Text] [Related]
12. Natural history and treatment of bone complications in prostate cancer.
Saad F; Clarke N; Colombel M
Eur Urol; 2006 Mar; 49(3):429-40. PubMed ID: 16431012
[TBL] [Abstract][Full Text] [Related]
13. Radium-223 dichloride for the treatment of metastatic prostate cancer.
Turner PG; O'Sullivan J
Expert Opin Pharmacother; 2014 Oct; 15(14):2105-11. PubMed ID: 25186336
[TBL] [Abstract][Full Text] [Related]
14. Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer.
Cook LM; Araujo A; Pow-Sang JM; Budzevich MM; Basanta D; Lynch CC
Sci Rep; 2016 Jul; 6():29384. PubMed ID: 27411810
[TBL] [Abstract][Full Text] [Related]
15. New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?
van Dodewaard-de Jong JM; Verheul HMW; Bloemendal HJ; de Klerk JMH; Carducci MA; van den Eertwegh AJM
Clin Genitourin Cancer; 2015 Aug; 13(4):271-279. PubMed ID: 25704270
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapeutic strategies for prostate cancer.
Nelson WG
Clin Adv Hematol Oncol; 2005 Aug; 3(8):619-21. PubMed ID: 16167046
[No Abstract] [Full Text] [Related]
17. Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges.
Massari F; Maines F; Modena A; Brunelli M; Bria E; Artibani W; Martignoni G; Tortora G
Anticancer Agents Med Chem; 2013 Jul; 13(6):872-86. PubMed ID: 23272970
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases.
Zustovich F; Fabiani F
Crit Rev Oncol Hematol; 2014 Aug; 91(2):197-209. PubMed ID: 24503416
[TBL] [Abstract][Full Text] [Related]
19. Molecular evidence-based use of bone resorption-targeted therapy in prostate cancer patients at high risk for bone involvement.
Karamanolakis D; Bogdanos J; Sourla A; Milathianakis C; Tsintavis A; Lembessis P; Tenta R; Tiblalexi D; Koutsilieris M
Mol Med; 2002 Nov; 8(11):667-75. PubMed ID: 12520083
[TBL] [Abstract][Full Text] [Related]
20. An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer.
Araujo A; Cook LM; Lynch CC; Basanta D
Cancer Res; 2014 May; 74(9):2391-401. PubMed ID: 24788098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
